Overview A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016) Status: Completed Trial end date: 2003-04-01 Target enrollment: Participant gender: Summary A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.